Aurora Cannabis (ACB) Q1 2027 Earnings Call Transcript
Aurora Cannabis (ACB) reported Q1 fiscal 2027 net revenue of $67.6 million, with international medical cannabis up 17% while Canada consumer revenue declined. International net revenue was $43 million and 64% of total revenue came from outside Canada. Adjusted gross margin was 58%, adjusted EBITDA $3.4 million, cash nearly $150 million, and zero debt. The board formed a special committee to review Curaleaf’s unsolicited $4.00/share bid.
How this was made
The 30-second read
Why it matters
Key disclosed items for traders are the Canadian VAC reimbursement rate reduction (30% effective April 1), the resulting drop in adjusted EBITDA and adjusted net income, and the board forming a special committee to evaluate Curaleaf’s implied offer structure.
Market read
The transcript provides actionable datapoints on revenue mix, margin, Canadian reimbursement headwinds, and takeover-process next steps.
What to watch
The Curaleaf proposal includes a value cap and incomplete consideration details, so deal probability and economics may be less certain than the headline offer implies.
Background
Aurora Cannabis held an earnings call for fiscal Q1 2027 (period ended June 30, 2026), discussing financial performance, international expansion in Germany, and an unsolicited takeover proposal from Curaleaf.
Ticker impact
Aurora Cannabis reported Q1 FY2027 results, including $67.6M net revenue and a 30% VAC reimbursement rate cut, plus an unsolicited Curaleaf bid.
Choppy-to-down bias if investors focus on weaker adjusted EBITDA and Canadian pricing, but takeover optionality can cap downside.
The call discloses concrete financial metrics (revenue, adjusted EBITDA, FCF use) and a specific unsolicited offer price framework, both of which can drive sentiment and positioning into the next corporate-action steps.
Market effects
Highlights ongoing regulatory and reimbursement pressure in Canadian medical cannabis, while emphasizing capacity expansion and yield improvements in Germany.
Germany is framed as the fastest-growing international market, with Leuna and EU GMP capacity expansion supporting supply.
Reinforces the global medical cannabis shift toward international markets and potential US federal rescheduling optionality.
Counterpoint
Investors may underweight the Canadian headwind because the company frames it as transitionary, while international revenue mix and adjusted gross margin are described as stabilizing at guidance highs.
Key entities
- companyAurora Cannabis Inc.
Subject of the earnings call transcript, reporting Q1 FY2027 results and discussing international expansion and a Curaleaf takeover proposal.
- companyCuraleaf Holdings, Inc.
Named bidder in an unsolicited acquisition proposal with implied consideration of US$4.00 per share framework.
- personMiguel Martin
Executive Chairman and CEO who discussed international growth, yield improvements, and the takeover bid details.
- personSimona King
CFO who discussed the Canadian pricing impact and adjusted financial metrics.
